DoW Orthopaedic, Clinical Research Award

The Orthopaedic Research Program Clinical Research Award is a federal funding opportunity administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs. This program is part of a broader initiative established by Congress to advance high-impact medical research relevant to military health, particularly in the area of orthopaedic injuries sustained during combat or service-related activities. Since its inception, the Orthopaedic Research Program has received substantial federal appropriations to support research that improves recovery outcomes and enhances return-to-duty capabilities for Service Members. The Clinical Research Award represents a newly structured mechanism designed to replace earlier translational and clinical trial funding pathways. The primary purpose of this funding opportunity is to support clinical research and clinical trials that evaluate orthopaedic-specific factors, treatments, and interventions. The program emphasizes generating clinically useful evidence that can directly inform patient care, influence clinical guidelines, and improve health outcomes. Projects must clearly demonstrate their potential to reduce the burden of orthopaedic injuries and improve functional recovery, particularly for military populations, though benefits to the broader public are also expected. Applicants must align their proposed research with at least one designated focus area, such as ligamentous trauma, osseointegration outcomes, return-to-duty strategies, limb stabilization, or military women’s health. Funding is offered across two research levels. Research Level 1 supports clinical research studies, while Research Level 2 supports clinical trials. The program anticipates funding approximately five awards total, with separate funding pools for each level. Awards may provide up to two million dollars for Level 1 projects and up to three point two million dollars for Level 2 projects, with a maximum performance period of four years. Funds may be used for a range of allowable costs including personnel, research activities, participant compensation, and limited travel related to dissemination of results. However, funding cannot be used for animal research, and strict guidelines govern allowable travel and cost structures. Eligibility for this opportunity is broad and inclusive. Both domestic and international organizations may apply, including public and private institutions, nonprofit and for-profit entities, and federal organizations. Independent investigators at any career stage may serve as Principal Investigators, provided they are affiliated with an eligible organization. There are no citizenship restrictions, and there is no limit on the number of applications an investigator may submit. Importantly, cost sharing is not required for participation, reducing barriers for applicants. The application process follows a two-step submission model. Applicants must first submit a pre-application through the Electronic Biomedical Research Application Portal, which includes a concise narrative outlining the research concept, objectives, and anticipated impact. Selected applicants will then be invited to submit a full application through either Grants.gov or eBRAP, depending on organizational type. The full application requires extensive documentation, including a detailed project narrative, study design, statistical plan, recruitment strategy, regulatory considerations, and supporting documentation such as letters of support and data sharing plans. Applications are evaluated through a rigorous two-tier review process. The first tier is peer review, which assesses scientific merit, feasibility, study design, and potential impact. The second tier is programmatic review, which considers alignment with program priorities, portfolio balance, and military relevance. Key evaluation criteria include research strategy, clinical impact, feasibility, recruitment planning, statistical rigor, ethical considerations, and potential for translation into practice. Successful applicants can expect notification following programmatic review, with awards anticipated to be made by September 2027. The timeline for this funding opportunity includes a pre-application deadline in August 2026 and a full application deadline in November 2026. Peer review is expected to occur in early 2027, followed by programmatic review shortly thereafter. Awards are expected to be issued within the same fiscal cycle. This funding opportunity is part of an annual federal appropriations process, suggesting that similar opportunities may be offered in future years, subject to congressional funding and program priorities.

Ensure strong alignment with focus areas; demonstrate clear clinical impact and relevance to military populations; include robust preliminary data and feasible study design; clearly define endpoints and statistical plan